Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.57 |
| ▸ | MST1R | Q04912 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | FECH | P22830 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448783 | 0.89 | MET (0.67) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4316394 | 0.87 | MET (0.56) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4308766 | 0.82 | MTOR (0.43) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4312490 | 0.82 | MET (0.45) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13859978 | 0.82 | PDE10A (0.40) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL399354 | 0.81 | MET (0.78) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4322496 | 0.80 | MET (0.55) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4313284 | 0.80 | MET (0.44) | METMST1R | |
| SCHEMBL5067593 | 0.80 | MET (0.39) | METMST1RCYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4307875 | 0.78 | FGFR3 (0.56) | METMST1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | MERCK & CO., INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007050383-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131423-A1 | Tyrosine Kinase Inhibitors | ABL1, ERBB2, MET | MET 3/4885MST1R 273/4885CYP3A4 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.